C4 Therapeutics (CCCC) Return on Sales (2020 - 2025)
Historic Return on Sales for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to 2.86%.
- C4 Therapeutics' Return on Sales fell 12600.0% to 2.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.96%, marking a year-over-year decrease of 8200.0%. This contributed to the annual value of 2.96% for FY2024, which is 34200.0% up from last year.
- Per C4 Therapeutics' latest filing, its Return on Sales stood at 2.86% for Q3 2025, which was down 12600.0% from 4.03% recorded in Q2 2025.
- C4 Therapeutics' Return on Sales' 5-year high stood at 0.78% during Q4 2021, with a 5-year trough of 13.48% in Q2 2023.
- Over the past 5 years, C4 Therapeutics' median Return on Sales value was 3.64% (recorded in 2025), while the average stood at 5.16%.
- Per our database at Business Quant, C4 Therapeutics' Return on Sales tumbled by -122500bps in 2022 and then skyrocketed by 120100bps in 2024.
- C4 Therapeutics' Return on Sales (Quarter) stood at 0.78% in 2021, then crashed by -1571bps to 13.03% in 2022, then grew by 18bps to 10.66% in 2023, then skyrocketed by 37bps to 6.68% in 2024, then soared by 57bps to 2.86% in 2025.
- Its last three reported values are 2.86% in Q3 2025, 4.03% for Q2 2025, and 3.64% during Q1 2025.